Ekso Bionics (EKSO) – Press Releases
-
Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal
-
Ekso Bionics Reports Record Annual Revenue of $18.3 Million
-
Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
-
Ekso Bionics Announces $4.6 Million Registered Direct Offering
-
Ekso Bionics Launches GaitCoach Software for EksoNR
-
Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results
-
Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal
-
Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29
-
Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal
-
Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38%
-
Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023
-
Ekso Bionics Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Include Personal Exoskeletons within a Medicare Benefit Category
-
Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
-
Ekso Bionics Reports Record Revenues of $4.7 Million in Second Quarter 2023
-
Ekso Bionics to Report Second Quarter 2023 Financial Results on July 27, 2023
-
Ekso Bionics Announces 61% Increase in First Quarter 2023 Revenues
-
Ekso Bionics to Report First Quarter 2023 Financial Results on April 27, 2023
-
Ekso Bionics Announces Ekso Indego Therapy Order by SoldierStrong
-
Ekso Bionics Reports Fourth Quarter and Year End 2022 Results
-
Ekso Bionics to Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
-
Ekso Bionics to Showcase Integrated Functional Electrical Stimulation for Indego Therapy at APTA Meeting
-
Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation
-
Ekso Bionics Reports Third Quarter 2022 Results
-
Ekso Bionics to Report Third Quarter 2022 Financial Results on November 3, 2022
-
Ekso Bionics to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Ekso Bionics Reports Second Quarter 2022 Results
-
Ekso Bionics to Report Second Quarter 2022 Financial Results on July 28
-
Ekso Bionics Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton for Use with Multiple Sclerosis Patients
-
Ekso Bionics Appoints Jerome Wong Interim Chief Financial Officer
-
Ekso Bionics to Present at the H.C. Wainwright Global Investment Conference
-
Ekso Bionics Reports First Quarter 2022 Results
-
Ekso Bionics to Report First Quarter 2022 Financial Results on April 28
-
Ekso Bionics Reports Fourth Quarter and Year End 2021 Results
-
Ekso Bionics to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
-
Ekso Bionics Announces Leadership Transition
-
Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2021 Financial Results
-
Ekso Bionics to Participate at the H.C. Wainwright BioConnect Virtual Conference
-
Ekso Bionics Appoints Corinna E. Lathan, Ph.D. to its Board of Directors
-
Ekso Bionics Announces EksoNR Multi-Unit Order by Nebraska Fraternal Order of Eagles
-
Ekso Bionics Reports Third Quarter 2021 Results
-
Ekso Bionics to Report Third Quarter 2021 Financial Results on November 2, 2021
-
Ekso Bionics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Ekso Bionics Reports Second Quarter 2021 Results
-
Ekso Bionics to Report Second Quarter 2021 Financial Results on July 29, 2021
-
Ekso Bionics Reports First Quarter 2021 Results
-
Ekso Bionics to Report First Quarter 2021 Financial Results on April 29, 2021
-
Ekso Bionics Announces Partnership with U.S. Physiatry to Support Physician Education of EksoNR
-
Ekso Bionics Teams Up with Performance Contracting, Inc. for Innovative Testing Approach of EVO™ Technology
-
Ekso Bionics to Present at the H.C. Wainwright Global Life Sciences Conference
-
Ekso Bionics® to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Back to EKSO Stock Lookup